Search Videos and More
News
FDA Approval Offers Hope For Prevention of Acute Graft-Versus-Host Disease
Based on a clinical trial led by Leslie S. Kean, MD, PhD, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, the FDA has approved abatacept for the prevention of GVHD. This approval will allow many more patients to safely and effectively undergo stem cell transplants, particularly patients of diverse ethnicities who have more difficulty finding appropriately matched donors.
News
Drug Combination Found to Keep Chronic Lymphocytic Leukemia in Young Patients in Remission for Several Years
A new study by Dana-Farber Cancer Institute researchers suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions for patients with chronic lymphocytic leukemia (CLL).
News
Molecular Analysis Advances Risk Profiling and Assessment of Immunotherapy Response in Smoldering Myeloma
Molecular and genetic research by scientists at Dana-Farber Cancer Institute has advanced the categorization of different risk groups in patients with smoldering myeloma, a premalignant condition that can – but doesn’t always – progress to the blood cancer, multiple myeloma.
News
American Society of Hematology (ASH) Annual Meeting
As leaders in blood and blood cancer research, physicians and scientists from Dana-Farber Cancer Institute shared advances and insights at the 63rd Annual Meeting of the American Society of Hematology (ASH) on December 11–14, 2021 in Atlanta, Georgia
News
New Study Reveals Elevated Rates of Blood Cancer Precursor Condition in Groups at High Risk for Multiple Myeloma
The first results from the largest screening study yet conducted in the United States of individuals at above-average risk for the blood cancer multiple myeloma have revealed higher rates of a myeloma precursor condition in older adults who are Black or who have a close family member with a current or past blood cancer.
News
Study Identifies Factors in Tumors’ Response to Natural Killer Cells
The immune cells known as natural killer (NK) cells are part of the body’s first line of defense against cancer. Many efforts are underway to harness NK cells as a form of cancer immunotherapy, but a critical question in the field remains: Why do some tumors tend to be sensitive to NK cells’ attacks while others are more resistant?
News
Dana-Farber Researchers Present Findings at San Antonio Breast Cancer Symposium
Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 44th annual San Antonio Breast Cancer Symposium on December 7-10th.
News
Dana-Farber’s Judy Garber Is Recipient Of Brinker Award For Scientific Distinction
This year’s Brinker Award for Scientific Distinction in Clinical Research is being presented today to Judy Garber, M.D., M.P.H., Chief of the Division of Cancer Genetics and Prevention at Dana Farber Cancer Institute.
News
Tamoxifen May Boost PI3K Signaling to Increase Uterine Cancer Risk in Some Patients
Uterine cancers that developed in patients treated with tamoxifen had fewer PI3K pathway mutations and may have instead been driven by tamoxifen-induced PI3K pathway activation, according to results presented at the 2021 San Antonio Breast Cancer Symposium.
News
Implantable Device Helps Predict Drug Therapy Efficacy
Dana-Farber investigators recently launched a trial of a miniature device that can be implanted into ovarian tumors to deliver microdoses of different drugs, with the goal of rapidly measuring their effectiveness in killing cancer cells.
Document
ASH 2021 Featured Oral Presentations
The Annual Meeting of the American Society of Hematology (ASH) will take place December 11-14th. To keep-up with latest advances, the live schedule of oral presentations by Dana-Farber faculty is attached for your convenience.
News
Targeted Drug Combination Shows Unprecedented Activity in Some Highly Aggressive Brain Tumors
Treatment with dabrafenib and trametinib yielded encouraging rate of durable responses in both high-grade and low-grade brain tumors carrying the rare BRAF v600E mutation. Study is first to show benefit of any targeted drugs in glioblastomas – the most aggressive brain tumor.